Autumn is here! Curl up with your Labubu’s favorite pumpkin-spiced blog and savor these stories harvested from the great Drug Channels patch: Mark Cuban’s company trims third-party fat but insured patients sometimes pay more Express Scripts boots Stelara, but clings to its biosimilar pricing double standard Thanks, IRA! The Part D market keeps unravelling Fresh insights from two government reports on the 340B Drug Pricing Program Plus: If you loved The Pitt, you'll love the sequel! P.S. J...
